Kyowa Hakko Bio Co. Ltd. engages in the manufacture and sale of amino acids and nucleic acids for pharmaceutical and industrial use. The company was founded on October 1, 2008 and is headquartered in Tokyo, Japan.

Kaneka Corp. engages in the manufacture and sale of chemicals, synthetic resins, and plastics. It operates through the following segments: Material Solutions, Quality of Life Solutions, Health Care Solutions, Nutrition Solutions and Others. The Material Solutions segment covers biodegradable polymers, materials that support the development of social infrastructure and mobility which includes the weight reduction and fuel efficiency improvement. The Quality of Life Solutions segment handles energy saving needs such as housing and living infrastructure, and development of Internet of things (IoT) and artificial intelligence (AI). The Health Care Solutions segment offers solutions through the fusion of devices and medicines, and develops healthcare business based on biopharmaceuticals and regenerative and cellular medicines. The Nutrition Solutions segment provides materials and supplement solutions to food production support in livestock and fishery industries. The Others segment provides agency services for property and life insurance. The company was founded on September 1, 1949 and is headquartered in Osaka, Japan.

Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.

The Group's principal activity is to produce pharmaceuticals and chemicals. The operations are carried out through the following divisions: Pharmaceuticals; Bio chemical; Chemicals; Food and Other. Pharmaceuticals include ethical drugs, bulk pharmaceuticals and biological research. Bio chemicals deal with biochemical diagnostic reagents, animal health products, agrochemicals and fertilizers. Chemicals includes solvents, plasticizes and their raw materials, detergent raw materials and specialty chemicals. Food includes alcoholic beverages, alcohol, seasonings, confectionery, baking ingredients and processed foods. Others include wholesale, commodity distribution and installation of facilities.

Established in 1937, KOHJI Co., Ltd. manufactures, processes, and sells products that are used as functional materials for the production of goods that support one's everyday life, such as flavor enhancers, health supplements, food packaging film for maintaining safety and freshness, functional chemicals and materials for commercial and residential building and furniture, paint, and household supplies such as shampoo. KOHJI is based in Tokyo and operates around Japan through its offices and factories in Osaka, Aichi, Kyushu, Kumamoto, and Ooita Prefectures

Senju Pharmaceutical Beijing Co. Ltd., part of Senju Pharmaceutical Co., Ltd., is a company headquartered in Beijing, China, that manufactures and distributes pharmaceuticals.

Promega Contributing to the prevention, healing and more. Founded in 1978, which began with the production of enzymes for research, has evolved into a catalog of over 2,000 products for a wide range of applications, including basic research, drug discovery, forensics, paternity testing and diagnosis clinician.

OXIS International SA is a French company located in Paris that develops and markets neutraceutical products for oxidative stress reduction. It was founded in 1989.

Sinyang Semiconductor Materials manufactures and provides sales services for functional chemical material products and application technologies required by the semiconductor industry. They provide integrated solutions for chemical materials, supporting equipment, application processes, and on-site services.

Nippon Paper Group is a diversified international timber, pulp, paper, paperboard packaging and chemicals business with operations in Asia, Oceania, North and South America and Europe. Headquartered in Tokyo, Japan, Nippon Paper was founded in 1949 and is listed on the Tokyo Stock Exchange with net sales of approx. $15 billion AUD. Nippon Paper Group is committed to global expansion through its key growth areas of packaging, household paper and healthcare, chemicals, energy, and wood products. Past acquisitions have included Australian Paper in 2009 for approx. $700 million AUD and the Weyerhaeuser liquid packaging board business in 2016 for $285 million USD. The purchase of Orora's Australasian Fibre Packaging business will be the Group's largest investment outside Japan.

Genematrix is developing new diagnostic products for various diseases by developing a globally competitive core platform technologies in the field of molecular diagnostics, which is attracting attention as a high-technology in the line of biotechnology. The Molecular Diagnostic market has high growth rates among in-vitro diagnostics markets and is a high value-added industry that is highly dependent on advanced countries since global companies prevailed the most core technologies. Genematrix, since the beginning of the company, has developed its own technologies that is globally competitive in the field of molecular diagnostics through joint research with domestic and international companies and research institutes.

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

BIOCEUTICALS Arzneimittel AG manufactures the active ingredient erythropoietin and markets it particularly by issuing sales licenses to STADAPHARM and other third parties.

AMES is a one-stop aircraft maintenance, repair, and overhaul (MRO) provider operating out of Wilmington, OH, with additional line maintenance operations in Cincinnati, OH, and Miami, FL. AMES holds a Part 145 FAA Repair certificate and provides heavy maintenance, line maintenance, material sales and service, component repair and overhaul, and engineering services to aircraft operators.

Japan Energy Corp. refines and distributes crude oil. The company engages in petroleum exploration & development, refining, and petroleum product sales to liquefied petroleum gas, lubricants, and petrochemical products. It was founded in December, 1905 and is headquartered in Tokyo, Japan

Develops and manufactures drugs related to immunology, neurobiology and oncology

Sanko is a manufacturer and seller of press products, mechatronics products, and plastic products. Their product and technology categories include press products, plastic products, and mechanism development design proposals. Their equipment lists such as press product mass production equipment, mass production equipment for plastic products, and mold manufacturing equipment.